A daily GLP-1 pill helped people with type 2 diabetes lose up to 8% of body weight.
The drug, orforglipron, outperformed oral semaglutide in a year-long phase 3 study.
Eli Lilly developed the tablet, which lowers blood sugar and reduces appetite.
Patients can take it without fasting, which simplifies treatment.
More than 1,500 participants joined the international trial.
Those taking orforglipron achieved stronger weight loss and better glucose control.
However, more patients stopped the drug because of stomach-related side effects.
Regulators have not yet approved orforglipron.
Experts say effective pills could replace injections and improve access.
Researchers still need long-term safety and cardiovascular data.
Specialists expect incretin-based tablets to become key diabetes therapies soon.
